CANbridge to Start China Phase II/III Trial of GBM Treatment

CANbridge Life Sciences of Beijing was granted China approval of an IND to start a Phase II/III trial of its lead candidate, CAN008, in patients with glioblastoma multiforme (GBM). The approval was based on a small (10 patient) Phase I trial of CAN008 in Taiwan , an example of China-Taiwan regulatory cooperation. In the trial, CAN008 did not show any safety problems. CAN008 is a TNF-blocker that is thought to restore the immune system's anti-tumor response. Two years ago, CANbridge in-licensed greater China rights to CAN008 from Germany 's Apogenix. More details.... Share this with colleagues: // //